Meptin Adverse Reactions

In clinical trials involving 22,575 patients, a total of 644 patients (2.83%) showed adverse reactions, including abnormal laboratory values. (At the time of approval of the initial application, completion of re-examination and approval of an additional indication for oral formulations of Meptin tablet and syrup.
The following summary of data includes adverse reactions reported after marketing without incidence rates.
Clinically Significant Adverse Reactions (*Incidence Unknown): Shock, Anaphylactoid Reactions: Shock or anaphylactoid reactions may occur. Patients should therefore be closely monitored. If abnormal findings are observed, Meptin should be discontinued and appropriate measures taken.
Significant decreases in serum potassium levels have been reported in patients receiving Meptin. If xanthine derivatives, corticosteroids or diuretics are co-administered with this drug in patients with severe asthma, extreme care is necessary to minimize the possibility of aggravating the decrease in serum potassium levels induced by β₂-adrenergic agonists. Serum potassium levels should be closely monitored in hypoxic patients, in view of the possible aggravation of cardiac arrhythmias secondary to a decrease in serum potassium levels.
Other Adverse Reactions: The following table shows the adverse reactions for tablets: (see Table 1).

Click on icon to see table/diagram/image

The following table shows the adverse reactions for syrup: (see Table 2).

Click on icon to see table/diagram/image